Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma

Lignende værker

• ATCT-35 QUALITY OF LIFE, COGNITIVE FUNCTION AND FUNCTIONAL STATUS IN THE EF-14 TRIAL: A PROSPECTIVE, MULTI-CENTER TRIAL OF TTFIELDS WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GBM
  af: Zhu, Jay-Jiguang, et al.
  Udgivet: (2015)
• The Added Value of Concurrently-Administered Temozolomide Versus Adjuvant Temozolomide Alone in Newly-Diagnosed Glioblastoma
  af: Sher, David J., et al.
  Udgivet: (2008)
• Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
  af: Haggiagi, Aya, et al.
  Udgivet: (2020)
• LTBK-01: PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
  af: Stupp, Roger, et al.
  Udgivet: (2016)
• CTNI-68. EFFICACY OF TTFIELDS IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) – SUB-GROUP ANALYSIS OF THE EF-14 TRIAL
  af: Ram, Zvi, et al.
  Udgivet: (2020)